Revisiting the Role of Valeric Acid in Manipulating Ulcerative Colitis

Area of Science:

• Gastroenterology
• Immunology
• Microbiology

Background:

• Ulcerative colitis (UC) involves complex interactions of inflammation, epithelial dysfunction, immune responses, and gut dysbiosis.
• The role of valeric acid (VA), a short-chain fatty acid (SCFA), in UC pathogenesis is not fully understood.

Purpose of the Study:

• To investigate the pathological role and underlying mechanisms of VA in ulcerative colitis.
• To evaluate the therapeutic potential of VA in UC models.

Main Methods:

• Analysis of SCFA levels in human UC patients and murine colitis models.
• Intervention with VA in murine colitis models and macrophage adoptive transfer experiments.
• Assessment of macrophage activation and inflammatory markers like interleukin-6 (IL-6).

Main Results:

• Alterations in SCFAs, including VA, were observed in UC patients and models.
• VA levels negatively correlated with UC disease severity, monocyte population, and IL-6 levels.
• VA treatment suppressed LPS-activated immune cells and ameliorated DSS-induced colitis by upregulating GPR41/GPR43 and modulating IL-6 production.

Conclusions:

• VA plays a pathological role in modulating macrophage activation in UC.
• VA demonstrates potential as an effective therapeutic agent for ulcerative colitis.